CST Principal Scientist Alissa Nelson, PhD, shows how combining antibody-based assays with DIA LC‑MS and PTMScan® ubiquitin profiling can fully characterize an androgen receptor degrader—from on‑target activity to off‑target substrates and site‑level ubiquitination changes.